Hepatitis C News

New data suggest that failure to achieve sustained virologic response after treatment with direct-acting antivirals for hepatitis C was a strong predictor for development of hepatocellular carcinoma.

Patients with hepatitis C virus have always carried an increased risk for developing hepatocellular carcinoma. Although antiviral treatment for HCV reduces that risk, it is not eliminated.

The front page of Infectious Disease News was dominated this year by stories about COVID-19 and its impact on health care.

The prevalence of hepatitis C infections has declined globally, but countries must scale up rates of diagnosis and treatment to achieve the WHO targets to eliminate HCV by 2030, according to new data.

Healio spoke with Nancy S. Reau, MD, FAASLD, AGAF, about results from a study examining maternal and childhood outcomes of hepatitis C presented at The Liver Meeting Digital Experience.

In this video, Nancy S. Reau, MD, FAASLD, AGAF, discussed one of the themes from The Liver Meeting Digital Experience: the effect of the COVID-19 pandemic on hepatitis C care.

Healio spoke with Nancy S. Reau, MD, FAASLD, AGAF, about a study evaluating a hepatitis C retreatment regimen in patients who failed therapy with Vosevi.

In this video, Nancy S. Reau, MD, FAASLD, AGAF, discussed a study presented at The Liver Meeting Digital Experience demonstrating the effectiveness of a rapid treatment model in engaging people who inject drugs in treating their hepatitis C virus.

For patients with hepatitis C, universal screening and the integration of clinical pharmacists may improve access to direct-acting antiviral therapy and help patients achieve sustained virologic response, according to a poster presentation.

In patients with hepatitis C infection who failed treatment with Vosevi, retreatment with a regimen of Sovaldi plus Mavyret plus ribavirin for 16 to 24 weeks was safe and effective, researchers reported.